NEX-18a injection + Azacitidine Injection

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 23/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Myelodysplastic Syndromes (MDS)

Conditions

Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), Acute Myeloid Leukemia (AML)

Trial Timeline

Apr 27, 2021 → Feb 10, 2022

NCT ID

NCT05048498

About NEX-18a injection + Azacitidine Injection

NEX-18a injection + Azacitidine Injection is a phase 1 stage product being developed by Nanexa AB for Myelodysplastic Syndromes (MDS). The current trial status is completed. This product is registered under clinical trial identifier NCT05048498. Target conditions include Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), Acute Myeloid Leukemia (AML).

What happened to similar drugs?

7 of 19 similar drugs in Myelodysplastic Syndromes (MDS) were approved

Approved (7) Terminated (7) Active (7)

✅decitabine + azacitidineEisaiApproved

✅DeferasiroxNovartisApproved

✅ICL670/DeferasiroxNovartisApproved

✅deferasiroxNovartisApproved

✅DeferasiroxNovartisApproved

✅Epoetin betaRocheApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05048498	Phase 1	Completed	Apr 27, 2021	Feb 10, 2022	Myelodysplastic Syndromes (MDS)

Competing Products

20 competing products in Myelodysplastic Syndromes (MDS)

See all competitors

Product	Company	Stage	Hype Score
JSP191	Jasper Therapeutics	Phase 1	11
Humanized anti-CD117 Monoclonal Antibody (JSP191)	Jasper Therapeutics	Phase 1	15
GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase II	GT Biopharma	Phase 1/2	14
Erlotinib Hydrochloride	Astellas Pharma	Phase 2	35
Decitabine + Decitabine + Decitabine	Eisai	Phase 2	35
Decitabine + Valproic Acid	Eisai	Phase 2	35
decitabine + decitabine	Eisai	Phase 2	35
decitabine + azacitidine	Eisai	Approved	35
Decitabine	Eisai	Phase 2	27
decitabine + decitabine + decitabine + decitabine	Eisai	Phase 1	29
Decitabine, Arsenic Trioxide and Ascorbic Acid	Eisai	Phase 2	35
Subcutaneous Decitabine	Eisai	Phase 1	21
Decitabine	Eisai	Phase 2	35
Galunisertib + Placebo	Eli Lilly	Phase 2/3	38
DSP-7888	Sumitomo Pharma	Phase 1/2	32
TP-0184	Sumitomo Pharma	Phase 1/2	24
Decitabine	Johnson & Johnson	Phase 2	35
Epoetin alfa	Johnson & Johnson	Phase 2	27
ZARNESTRA, tipifarnib, R115777	Johnson & Johnson	Phase 2	35
Decitabine	Johnson & Johnson	Phase 2	27